[1] |
STRATER N. Ecto-5'-nucleotidase: Structure function relationships[J]. Purinergic Signalling, 2006, 2(2): 343-350. doi: 10.1007/s11302-006-9000-8
|
[2] |
KNAPPn K, ZEBISCH M, PIPPEL J, et al. Crystal structure of the human ecto-5′-nucleotidase (CD73): insights into the regulation of purinergic signaling[J]. Structure, 2012, 20(12): 2161-2173. doi: 10.1016/j.str.2012.10.001
|
[3] |
ZIMMERMANN H, ZEBISCH M, STRATER N, et al. Cellular function and molecular structure of ecto-nucleotidases[J]. Purinergic Signalling, 2012, 8(3): 437-502. doi: 10.1007/s11302-012-9309-4
|
[4] |
GAO Z, DONG K, ZHANG H, et al. The roles of CD73 in cancer[J]. BioMed Research International, 2014: 460654-460654.
|
[5] |
VIJAYAN D, YOUNG A, TENG M W, et al. Targeting immunosuppressive adenosine in cancer[J]. Nature Reviews Cancer, 2017, 17(12): 709-724. doi: 10.1038/nrc.2017.86
|
[6] |
CHALMIN F, MIGNOT G, BRUCHARD M, et al. Stat3 and Gfi-1 transcription factors control Th17 cell immunosuppressive activity via the regulation of ectonucleotidase expression[J]. Immunity, 2012, 36(3): 362-373. doi: 10.1016/j.immuni.2011.12.019
|
[7] |
SYNNESTVDT K, FURUTA G T, COMERFORD K M, et al. Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia[J]. The Journal of Clinical Investigation, 2002, 110(7): 993-1002. doi: 10.1172/JCI0215337
|
[8] |
REGATEIRO F S, HOWIE D, NOLAN K F, et al. Generation of anti‐inflammatory adenosine byleukocytes is regulated by TGF‐β[J]. European Journal of Immunology, 2011, 41(10): 2955-2965. doi: 10.1002/eji.201141512
|
[9] |
NIEMELA J, HENTTINEN T, YEGUTKIN G G, et al. IFN-α induced adenosine production on the endothelium: a mechanism mediated by CD73 (ecto-5′-nucleotidase) up-regulation[J]. The Journal of Immunology, 2004, 172(3): 1646-1653. doi: 10.4049/jimmunol.172.3.1646
|
[10] |
SPYCHALA J, KITAJEWSKI J. Wnt and β-catenin signaling target the expression of ecto-5′-nucleotidase and increase extracellular adenosine generation[J]. Experimental Cell Research, 2004, 296(2): 99-108. doi: 10.1016/j.yexcr.2003.11.001
|
[11] |
ALLARD D, CHROBAK P, ALLARD B, et al. Targeting the CD73-adenosine axis in immuno-oncology[J]. Immunology Letters, 2019: 31-39.
|
[12] |
CORBELINI P F, FIGUEIRO F, NEVES G M, et al. Insights into Ecto-5'-Nucleotidase as a New Target for Cancer Therapy: A Medicinal Chemistry Study[J]. Current Medicinal Chemistry, 2015, 22(15): 1776-1792. doi: 10.2174/0929867322666150408112615
|
[13] |
BURGER R M, LOWENSTEIN J M. Preparation and Properties of 5'-Nucleotidase from Smooth Muscle of Small Intestine[J]. Journal of Biological Chemistry, 1970, 245(23): 6274-6280. doi: 10.1016/S0021-9258(18)62605-5
|
[14] |
BHATTARAI S, FREUNDLIEB M, PIPPEL J, et al. α, β-Methylene-ADP (AOPCP) Derivatives and Analogues: Development of Potent and Selective ecto-5′-Nucleotidase (CD73) Inhibitors[J]. Journal of Medicinal Chemistry, 2015, 58(15): 6248-6263. doi: 10.1021/acs.jmedchem.5b00802
|
[15] |
JUNKER A, RENN C, DOBELMANN C, et al. Structure–Activity Relationship of Purine and Pyrimidine Nucleotides as Ecto-5′-Nucleotidase (CD73) Inhibitors[J]. Journal of Medicinal Chemistry, 2019, 62(7): 3677-3695. doi: 10.1021/acs.jmedchem.9b00164
|
[16] |
BHATTARAI S, PIPPEL J, SCALETTI E et al. 2-Substituted α, β-Methylene-ADP Derivatives: Potent Competitive Ecto-5'-nucleotidase (CD73) Inhibitors with Variable Binding Modes[J]. Journal of Medicinal Chemistry, 2020, 63(6): 2941-2957. doi: 10.1021/acs.jmedchem.9b01611
|
[17] |
BOWMAN C E, SILVA R G, PHAM A, et al. An Exceptionally Potent Inhibitor of Human CD73[J]. Biochemistry, 2019, 58(31): 3331-3334. doi: 10.1021/acs.biochem.9b00448
|
[18] |
KAVUTCU M, MELZIG M F. In vitro effects of selected flavonoids on the 5'-nucleotidase activity[J]. Pharmazie Die, 1999, 54(6): 457-459.
|
[19] |
RIPPHAUSEN P, FREUNDLIEB M, BRUNSCHWEIGER A, et al. Virtual screening identifies novel sulfonamide inhibitors of ecto-5′-nucleotidase[J]. Journal of Medicinal Chemistry, 2012, 55(14): 6576-6581. doi: 10.1021/jm300658n
|
[20] |
BAQI Y, LEE S Y, IQBAL J, et al. Development of potent and selective inhibitors of ecto-5′-nucleotidase based on an anthraquinone scaffold[J]. Journal of Medicinal Chemistry, 2010, 53(5): 2076-2086. doi: 10.1021/jm901851t
|
[21] |
GONG Y P, WAN R Z, LIU Z P. Evaluation of WO2017098421: GSK’s benzothiazine compounds as CD73 inhibitor filings[J]. Expert Opinion on Therapeutic Patents, 2018, 28(2): 167-171. doi: 10.1080/13543776.2018.1407756
|
[22] |
BEATTY J W, LINDSEY E A, THOMAS-TRAN R, et al. Discovery of Potent and Selective Non-Nucleotide Small Molecule Inhibitors of CD73[J]. Journal of Medicinal Chemistry, 2020, 63(8): 3935-3955. doi: 10.1021/acs.jmedchem.9b01713
|